

Cabozantinib promising for advanced adrenocortical carcinoma

April 29 2024, by Elana Gotkine



For patients with advanced adrenocortical carcinoma, cabozantinib shows promising efficacy, according to a [study](#) published online April 9 in *The Lancet Oncology*.

Matthew T. Campbell, M.D., from The University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a single-arm, Phase II trial in adults with advanced adrenocortical carcinoma who were not candidates for surgery with curative intent and had an estimated life expectancy of at least three months, as well as an Eastern Cooperative Oncology Group performance status of 0 to 2.

Patients were given oral cabozantinib 60 mg daily with the option of dose reduction for management of adverse events. Eighteen patients were enrolled between March 1, 2018, and May 31, 2021, with a median follow-up of 36.8 months.

The researchers found that 13 of the patients (72.2 percent) had progression-free survival at four months, and median [progression-free survival](#) was six months. One patient is still receiving treatment. Eleven patients (61 percent) had treatment-related adverse events of grade 3 or worse.

The most common grade 3 adverse events were lipase elevation, elevated γ -glutamyl transferase concentrations, elevated alanine aminotransferase concentrations, hypophosphatemia, and hypertension (17, 11, 11, 11, and 11 percent, respectively). Grade 4 [hypertension](#) occurred in one patient (6 percent). There were no treatment-related deaths reported.

"Cabozantinib in advanced adrenocortical carcinoma showed promising activity and a manageable safety profile," the authors write. "The possible immunomodulatory effect of cabozantinib, if proven, could have potential for [combination therapy](#) with [immunotherapy](#) in patients with adrenocortical [carcinoma](#)."

More information: Matthew T Campbell et al, Cabozantinib

monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial, *The Lancet Oncology* (2024). DOI: [10.1016/S1470-2045\(24\)00095-0](https://doi.org/10.1016/S1470-2045(24)00095-0)

Margaret E Wierman, Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer?, *The Lancet Oncology* (2024). DOI: [10.1016/S1470-2045\(24\)00151-7](https://doi.org/10.1016/S1470-2045(24)00151-7)

Copyright © 2024 [HealthDay](#). All rights reserved.

Citation: Cabozantinib promising for advanced adrenocortical carcinoma (2024, April 29) retrieved 17 May 2024 from <https://medicalxpress.com/news/2024-04-cabozantinib-advanced-adrenocortical-carcinoma.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.